Alzheimer's disease, a significant neuro degenerative illness impacting millions worldwide,
has seen promising progress with an innovative treatment pioneered by Dr. Daniel Casey, an
Interventional Psychiatrist associated with the Oxford TPS Clinic.
This condition is characterized by the buildup of abnormal proteins, like amyloid plaques
and neurofibrillary tangles in the brain, leading to disruptions in cerebral blood flow and
changes in the distribution of essential neurotrophic factors such as Brain-Derived
Neurotrophic Factor (BDNF), critical for brain function.
Storz Medical has introduced the Neurolith, an advanced medical device designed to
alleviate Alzheimer's symptoms and potentially slow cognitive decline. This therapy, called
Transcranial Pulse Stimulation (TPS), is non-invasive, delivering high-frequency acoustic
waves through the skull to stimulate neural growth factors.
Research by the University of Vienna suggests that just six 30-minute TPS treatments over
two weeks can improve mild to moderate Alzheimer's symptoms by up to 10 points on the
CERAD scale. Notably, improvements in memory, verbal function, and depression have been
observed, although further trials and long-term monitoring are necessary.
Furthermore, this innovative treatment shows promise in reducing depression symptoms in
Alzheimer's patients. By stimulating BDNF, integral to the procedure, it is believed to
enhance mood and decrease depressive manifestations, offering a comprehensive approach
to improving patient quality of life.
Utilizing the Neurolith system provided by Venn Healthcare Ltd., this treatment is non-
invasive and does not require medication or hair removal. Patients undergo comfortable
sessions, typically over two weeks with two treatments per week.
Dr. Daniel Casey, with expertise in Interventional Psychiatry from Oxford, is committed to
aiding patients with memory issues and neuropsychiatric symptoms. Engaged in
collaborative research with Dr. Eva Feredoes at the University of Reading, his focus is on
exploring the clinical applications of TPS. With a Master's degree in Neuroscience, Dr. Casey
is affiliated with esteemed medical organizations such as the Clinical TMS Society, the Royal
College of Psychiatrists (MRCPsych), and the Royal College of Physicians of London (MRCP
Lon).
Supported by Dr. Marco Fabus, a medical graduate from the University of Oxford, the
Oxford TPS Clinic offers assessment and treatment services for individuals facing memory-
related challenges. This treatment, approved in 2021, complements standard Alzheimer's
care and is part of a collaborative research initiative with the University of Reading to
evaluate TPS efficacy.
For international patients, numerous accommodation options are available in Oxford,
making access to the clinic convenient.
Individuals seeking information on NeuroPulse™ TPS® or its suitability are encouraged to
contact the Oxford TPS Clinic.
